PSTI has been the subject of several other reports. HC Wainwright reiterated a buy rating and set a $3.50 price objective on shares of Pluristem Therapeutics in a research note on Monday, May 15th. Zacks Investment Research downgraded shares of Pluristem Therapeutics from a buy rating to a hold rating in a research note on Thursday, April 13th.
Shares of Pluristem Therapeutics (NASDAQ:PSTI) opened at 1.40 on Monday. The stock’s market capitalization is $134.86 million. Pluristem Therapeutics has a 52 week low of $1.04 and a 52 week high of $1.85. The firm’s 50-day moving average is $1.40 and its 200-day moving average is $1.35.
COPYRIGHT VIOLATION WARNING: This story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://sportsperspectives.com/2017/05/26/pluristem-therapeutics-inc-psti-receives-hold-rating-from-maxim-group.html.
Hedge funds and other institutional investors have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Pluristem Therapeutics by 46.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 92,000 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 29,000 shares during the period. Jane Street Group LLC boosted its position in shares of Pluristem Therapeutics by 62.4% in the first quarter. Jane Street Group LLC now owns 108,830 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 41,796 shares during the period. Menora Mivtachim Holdings LTD. acquired a new position in shares of Pluristem Therapeutics during the first quarter valued at about $1,230,000. Finally, Renaissance Technologies LLC boosted its position in shares of Pluristem Therapeutics by 8.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,424,800 shares of the biotechnology company’s stock valued at $2,037,000 after buying an additional 113,300 shares during the period. 3.05% of the stock is owned by hedge funds and other institutional investors.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.